. Author manuscript; available in PMC: 2012 Jun 1.

Published in final edited form as: Pharmacogenet Genomics. 2011 Jun;21(6):333–340. doi: 10.1097/FPC.0b013e3283452fec

Table 3.

Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for primary outcomes by carrier status

	Adjusted OR (95% CI)	Adjusted p-value
rs11039149 (Variant G allele carriers vs. Wild Type)^*	0.64 (0.47-0.87)	0.004
rs12221497 (Variant A allele carriers vs. Wild Type)^*	0.69 (0.47-1.02)	0.064
rs2279238 (Variant T allele carriers vs. Wild Type)^*	1.34 (0.99-1.81)	0.060
rs7120118 (Variant T allele carriers vs. Wild Type)	1.16 (0.85-1.58)	0.351
rs326213 (Variant A allele carriers vs. Wild Type)	1.21 (0.41-3.58)	0.737
rs11039159 (Variant T allele carriers vs. Wild Type)	0.82 (0.60-1.11)	0.200
rs10501321 (Variant T allele carriers vs. Wild Type)	1.19 (0.87-1.62)	0.271

Odds Ratios (OR) from logistic regression adjusted for: age, sex, race/ethnicity, BMI, INVEST treatment strategy, history of CHF, history of MI and history of diabetes at baseline

Indicates p meets pre-specified significance level for subsequent testing in racial strata